Draupnir Bio, a Copehagen, Denmark-based biotechnology company harnessing the natural machinery of the lysosome to develop oral, small molecule degraders of extracellular disease-causing proteins, raised €12M in Seed funding.
Backers included MP Healthcare and EIFO and existing investors, Gilde Healthcare Partners, Inkef Capital and Novo Holdings.
The company intends to use the funds to further develop its risk-diversified preclinical pipeline of oral, small molecule protein degraders, which have been proven against targets that are validated and those that have been traditionally difficult to drug.
Led by CEO Andrew Hotchkiss, Draupnir Bio is biotechnology company developing oral, small molecule degraders of extracellular disease-causing proteins – the next frontier of targeted protein degradation (TPD), a rapidly emerging field that exploits a cell’s own destruction machinery to tackle disease-causing proteins that have historically been highly challenging to target with conventional therapies. It was spun-out from Aarhus University, Denmark and the Max-Planck Society.
FinSMEs
22/07/2024